D
David A. Ehst
Researcher at Argonne National Laboratory
Publications - 56
Citations - 846
David A. Ehst is an academic researcher from Argonne National Laboratory. The author has contributed to research in topics: Tokamak & Fusion power. The author has an hindex of 14, co-authored 56 publications receiving 814 citations.
Papers
More filters
Journal ArticleDOI
Overview of the ARIES-RS reversed-shear tokamak power plant study
Farrokh Najmabadi,Charles G. Bathke,Michael C. Billone,James Blanchard,Leslie Bromberg,Edward Chin,Fredrick R Cole,Jeffrey A. Crowell,David A. Ehst,Laila El-Guebaly,J. Stephen Herring,Thanh Q. Hua,Stephen Jardin,Charles Kessel,H.Y. Khater,V. Dennis Lee,Siegfried Malang,T. K. Mau,Ronald L. Miller,E. A. Mogahed,Thomas W Petrie,Elmer E Reis,J.H. Schultz,M. Sidorov,Don Steiner,I.N. Sviatoslavsky,Dai-Kai Sze,Robert Thayer,Mark S. Tillack,Peter H. Titus,Lester M Wagner,X.R. Wang,C.P.C. Wong +32 more
TL;DR: The ARIES-RS tokamak is a conceptual, D-T-burning 1000 MWe power plant as mentioned in this paper, which employs a reversed-shear plasma and employs a moderate aspect ratio (A40).
Journal ArticleDOI
Approximate formula for radiofrequency current drive efficiency with magnetic trapping
TL;DR: In this paper, a functional form for the efficiency of current drive in toroidal geometry with waves at frequencies below the electron cyclotron frequency is presented, by fitting constants in order to duplicate numerical results.
Journal ArticleDOI
Physics basis for a reversed shear tokamak power plant
Stephen Jardin,C.E. Kessel,Charles G. Bathke,David A. Ehst,T. K. Mau,Farrokh Najmabadi,T.W. Petrie +6 more
TL;DR: In this paper, the reversed shear plasma configuration is examined as the basis for a tokamak fusion power plant and a divertor solution is found which employs neon impurity injection to enhance the radiation in the scrape-off layer (SOL) and divertor and results in a combined particle and heat load in the divertor of 5 6M W m 2.
Journal ArticleDOI
The production, separation, and use of 67Cu for radioimmunotherapy: a review.
TL;DR: Widespread use of this isotope for clinical studies and preliminary treatments has been limited by unreliable supplies, cost, and difficulty in obtaining therapeutic quantities.
Journal ArticleDOI
The ARIES-I Tokamak Reactor Study†
Farrokh Najmabadi,Robert W. Conn,Charles G. Bathke,Leslie Bromberg,Edward T. Cheng,Daniel R. Cohn,P.I.H. Cooke,R.L. Creedon,David A. Ehst,K. Evans,Nasr M. Ghoniem,S.P. Grotz,M.Z. Hasan,J.T. Hogan,J. S. Herring,A.W. Hyatt,E. Ibrahim,S.A. Jardin,Charles Kessel,Marc Klasky,R.A. Krakowski,Tomoaki Kunugi,J.A. Leuer,J. Mandrekas,R.C. Martin,T. K. Mau,Ronald L. Miller,Y-K.M. Peng,R.L. Reid,John F. Santarius,M.J. Schaffer,J.H. Schultz,K.R. Schultz,Justin Schwartz,Shahram Sharafat,C.E. Singer,L. Snead,Don Steiner,Dennis J Strickler,D.K. Sze,M. Valenti,D.J. Ward,J.E.C. Williams,Layton J. Wittenberg,C.P.C. Wong +44 more
TL;DR: The ARIES-I project as discussed by the authors is a multi-institutional effort to develop several visions of tokamak reactors with enhanced economic, safety, and environmental features, including a high performance, low activation, SiC composite blanket cooled by He, and an advanced Rankine power cycle.